Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
OPTIC was born from a clinical question about how best to balance efficacy and long-term treatment management with ponatinib. Five-year follow-up now shows how response-based dosing evolved from a hypothesis into a validated treatment strategy for patients with resistant chronic-phase CML.
